If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> HEPATOLOGY<br /> ISSN 2053-4221 Vol 3.1 • January 2015 • emjreviews.com<br /> CONTENTS<br /> EDITORIAL BOARD................................................................................................................................. 4<br /> EDITOR’S PICK: NON-ALCOHOLIC FATTY LIVER DISEASE - CHANGING THE PREVALENCE<br /> OF LIVER CANCER?........................................................................................................................................ 12<br /> • Benedetta Campana et al.<br /> ALCOHOL DEPENDENCE AND ALCOHOLIC LIVER DISEASE.............................................................. 20<br /> • Karl Mann and Sebastian Mueller<br /> THE LIVER MEETING 2014: SUMMARY OF PRESENTATIONS ON GENOTYPE 3 HCV<br /> INFECTION FROM THE 65TH ANNUAL LIVER MEETING OF THE AMERICAN ASSOCIATION<br /> FOR THE STUDY OF LIVER DISEASES (AASLD), HELD IN BOSTON, MA, USA, ON 7T<a title="EMJ Hepatology 3.1 2015 page 1" href="http://viewer.zmags.com/publication/76f7d9a8?page=1"> HEPATOLOGY ISSN 2053-4221 </a> <a title="EMJ Hepatology 3.1 2015 page 2" href="http://viewer.zmags.com/publication/76f7d9a8?page=2"> CONTENTS EDITORIAL BOARD.......................</a> <a title="EMJ Hepatology 3.1 2015 page 3" href="http://viewer.zmags.com/publication/76f7d9a8?page=3"> HEPATOLOGY METABOLIC SYNDROME IN PAEDIATRIC POP</a> <a title="EMJ Hepatology 3.1 2015 page 4" href="http://viewer.zmags.com/publication/76f7d9a8?page=4"> Editorial Board Editor-in-Chief: Prof Dr M</a> <a title="EMJ Hepatology 3.1 2015 page 5" href="http://viewer.zmags.com/publication/76f7d9a8?page=5"> Hepatology Prof Dr Pierre-Alain Clavien, Prof</a> <a title="EMJ Hepatology 3.1 2015 page 6" href="http://viewer.zmags.com/publication/76f7d9a8?page=6"> European Medical Journal EMJ Hepatology Vol 3.1</a> <a title="EMJ Hepatology 3.1 2015 page 7" href="http://viewer.zmags.com/publication/76f7d9a8?page=7"> Welcome Future perspectives, new technology an</a> <a title="EMJ Hepatology 3.1 2015 page 8" href="http://viewer.zmags.com/publication/76f7d9a8?page=8"> SUBSCRIBE FREE TO OUR YOUTUBE CHANNEL www.youtube</a> <a title="EMJ Hepatology 3.1 2015 page 9" href="http://viewer.zmags.com/publication/76f7d9a8?page=9"> Dea Foreword Dr Kenneth J. S</a> <a title="EMJ Hepatology 3.1 2015 page 10" href="http://viewer.zmags.com/publication/76f7d9a8?page=10"> Look out for our additional eJournal</a> <a title="EMJ Hepatology 3.1 2015 page 11" href="http://viewer.zmags.com/publication/76f7d9a8?page=11"> Coming soon to the EMJ eJournal portfolio </a> <a title="EMJ Hepatology 3.1 2015 page 12" href="http://viewer.zmags.com/publication/76f7d9a8?page=12"> EDITOR’S PICK W</a> <a title="EMJ Hepatology 3.1 2015 page 13" href="http://viewer.zmags.com/publication/76f7d9a8?page=13"> Keywords: Non-alcoholic fatty liver disease, </a> <a title="EMJ Hepatology 3.1 2015 page 14" href="http://viewer.zmags.com/publication/76f7d9a8?page=14"> Pathophysiology The sequence of progression from </a> <a title="EMJ Hepatology 3.1 2015 page 15" href="http://viewer.zmags.com/publication/76f7d9a8?page=15"> with and without cirrhosis. The association betwe</a> <a title="EMJ Hepatology 3.1 2015 page 16" href="http://viewer.zmags.com/publication/76f7d9a8?page=16"> As discussed above, a genome-wide association stu</a> <a title="EMJ Hepatology 3.1 2015 page 17" href="http://viewer.zmags.com/publication/76f7d9a8?page=17"> dehydrogenase Type 1 (11β-HSD1) versus placebo in</a> <a title="EMJ Hepatology 3.1 2015 page 18" href="http://viewer.zmags.com/publication/76f7d9a8?page=18"> 2005;42(2):218-24. 29. European Association For T</a> <a title="EMJ Hepatology 3.1 2015 page 19" href="http://viewer.zmags.com/publication/76f7d9a8?page=19"> Would you like to write for the EMJ blog? Intera</a> <a title="EMJ Hepatology 3.1 2015 page 20" href="http://viewer.zmags.com/publication/76f7d9a8?page=20"> ALCOHOL DEPENDENCE AND ALCOHOLIC </a> <a title="EMJ Hepatology 3.1 2015 page 21" href="http://viewer.zmags.com/publication/76f7d9a8?page=21"> mental disorders.5 In a survey conducted from 200</a> <a title="EMJ Hepatology 3.1 2015 page 22" href="http://viewer.zmags.com/publication/76f7d9a8?page=22"> Objectives, design, and main endpoints The ESENSE</a> <a title="EMJ Hepatology 3.1 2015 page 23" href="http://viewer.zmags.com/publication/76f7d9a8?page=23"> and Improvement scales (CGI-S and CGI-I) in the n</a> <a title="EMJ Hepatology 3.1 2015 page 24" href="http://viewer.zmags.com/publication/76f7d9a8?page=24"> are of particular importance as they contra</a> <a title="EMJ Hepatology 3.1 2015 page 25" href="http://viewer.zmags.com/publication/76f7d9a8?page=25"> REFERENCES 1. Fleischmann A et al. Global </a> <a title="EMJ Hepatology 3.1 2015 page 26" href="http://viewer.zmags.com/publication/76f7d9a8?page=26"> liver. Lancet. 1986;1(8480):523-5. 41. Cadranel J</a> <a title="EMJ Hepatology 3.1 2015 page 27" href="http://viewer.zmags.com/publication/76f7d9a8?page=27"> THE LIVER MEETING 2014: Summary of the treatment </a> <a title="EMJ Hepatology 3.1 2015 page 28" href="http://viewer.zmags.com/publication/76f7d9a8?page=28"> interferon-based therapies, as the former require</a> <a title="EMJ Hepatology 3.1 2015 page 29" href="http://viewer.zmags.com/publication/76f7d9a8?page=29"> DCV was recently approved in Europe and Japan in </a> <a title="EMJ Hepatology 3.1 2015 page 30" href="http://viewer.zmags.com/publication/76f7d9a8?page=30"> response at the time of the presentation. Interva</a> <a title="EMJ Hepatology 3.1 2015 page 31" href="http://viewer.zmags.com/publication/76f7d9a8?page=31"> Table 2 continued. Study Treatment arms T</a> <a title="EMJ Hepatology 3.1 2015 page 32" href="http://viewer.zmags.com/publication/76f7d9a8?page=32"> comprised prior treatment-failures, including SOF</a> <a title="EMJ Hepatology 3.1 2015 page 33" href="http://viewer.zmags.com/publication/76f7d9a8?page=33"> was evaluated at Week 20 and reached 100% in the </a> <a title="EMJ Hepatology 3.1 2015 page 34" href="http://viewer.zmags.com/publication/76f7d9a8?page=34"> REFERENCES 1. Messina JP et al. Global distribut</a> <a title="EMJ Hepatology 3.1 2015 page 35" href="http://viewer.zmags.com/publication/76f7d9a8?page=35"> DEFINITIONS OF ACUTE-ON-CHRONIC LIVER FAILURE: </a> <a title="EMJ Hepatology 3.1 2015 page 36" href="http://viewer.zmags.com/publication/76f7d9a8?page=36"> hepatic organ failures are present. Three clinica</a> <a title="EMJ Hepatology 3.1 2015 page 37" href="http://viewer.zmags.com/publication/76f7d9a8?page=37"> Table 1: Different definitions of acute-on-chronic</a> <a title="EMJ Hepatology 3.1 2015 page 38" href="http://viewer.zmags.com/publication/76f7d9a8?page=38"> insult manifesting as jaundice (with bilirubin ≥5</a> <a title="EMJ Hepatology 3.1 2015 page 39" href="http://viewer.zmags.com/publication/76f7d9a8?page=39"> In the CLIF classification (CLIF-ACLF Grades)</a> <a title="EMJ Hepatology 3.1 2015 page 40" href="http://viewer.zmags.com/publication/76f7d9a8?page=40"> cirrhotic patients. In the same way, a study of t</a> <a title="EMJ Hepatology 3.1 2015 page 41" href="http://viewer.zmags.com/publication/76f7d9a8?page=41"> HEPATIC-BASED INBORN ERRORS OF METABOLISM </a> <a title="EMJ Hepatology 3.1 2015 page 42" href="http://viewer.zmags.com/publication/76f7d9a8?page=42"> FAP FAP is caused by a mutation in the gene that</a> <a title="EMJ Hepatology 3.1 2015 page 43" href="http://viewer.zmags.com/publication/76f7d9a8?page=43"> liver and brain.39 Recently, it has been shown th</a> <a title="EMJ Hepatology 3.1 2015 page 44" href="http://viewer.zmags.com/publication/76f7d9a8?page=44"> but robust evidence of efficacy is so far limited</a> <a title="EMJ Hepatology 3.1 2015 page 45" href="http://viewer.zmags.com/publication/76f7d9a8?page=45"> REFERENCES 1. Garrod AE. The incidence of alkapt</a> <a title="EMJ Hepatology 3.1 2015 page 46" href="http://viewer.zmags.com/publication/76f7d9a8?page=46"> its potential for Wilson’s disease. Ann N Y Acad </a> <a title="EMJ Hepatology 3.1 2015 page 47" href="http://viewer.zmags.com/publication/76f7d9a8?page=47"> If you are interested in submitting a paper to </a> <a title="EMJ Hepatology 3.1 2015 page 48" href="http://viewer.zmags.com/publication/76f7d9a8?page=48"> METABOLIC SYNDROME IN PAEDIATRIC POPULATION: IS I</a> <a title="EMJ Hepatology 3.1 2015 page 49" href="http://viewer.zmags.com/publication/76f7d9a8?page=49"> Until now more than 40 definitions for childhood M</a> <a title="EMJ Hepatology 3.1 2015 page 50" href="http://viewer.zmags.com/publication/76f7d9a8?page=50"> Old MetS scenario </a> <a title="EMJ Hepatology 3.1 2015 page 51" href="http://viewer.zmags.com/publication/76f7d9a8?page=51"> widely considered as the hepatic manifestation of</a> <a title="EMJ Hepatology 3.1 2015 page 52" href="http://viewer.zmags.com/publication/76f7d9a8?page=52"> obesity in childhood, studies evaluating </a> <a title="EMJ Hepatology 3.1 2015 page 53" href="http://viewer.zmags.com/publication/76f7d9a8?page=53"> In fact, low vitamin D levels have been linked wi</a> <a title="EMJ Hepatology 3.1 2015 page 54" href="http://viewer.zmags.com/publication/76f7d9a8?page=54"> liver disease and metabolic syndrome in adol</a> <a title="EMJ Hepatology 3.1 2015 page 55" href="http://viewer.zmags.com/publication/76f7d9a8?page=55"> PAEDIATRIC METABOLIC CONDITIONS OF THE LIVER </a> <a title="EMJ Hepatology 3.1 2015 page 56" href="http://viewer.zmags.com/publication/76f7d9a8?page=56"> deposition in Descemet’s membrane in the cornea, </a> <a title="EMJ Hepatology 3.1 2015 page 57" href="http://viewer.zmags.com/publication/76f7d9a8?page=57"> Table 2: Prerequisites for successful paediatric </a> <a title="EMJ Hepatology 3.1 2015 page 58" href="http://viewer.zmags.com/publication/76f7d9a8?page=58"> as ASs except for subtype 4 (Hers disease) which </a> <a title="EMJ Hepatology 3.1 2015 page 59" href="http://viewer.zmags.com/publication/76f7d9a8?page=59"> fumarylacetoacetase, the last enzyme in </a> <a title="EMJ Hepatology 3.1 2015 page 60" href="http://viewer.zmags.com/publication/76f7d9a8?page=60"> GLYCOPROTEIN DISORDERS Hepatic Aspects of Alpha-1</a> <a title="EMJ Hepatology 3.1 2015 page 61" href="http://viewer.zmags.com/publication/76f7d9a8?page=61"> and organs, leading to an impairment of th</a> <a title="EMJ Hepatology 3.1 2015 page 62" href="http://viewer.zmags.com/publication/76f7d9a8?page=62"> Ireland and the population history of the Ir</a> <a title="EMJ Hepatology 3.1 2015 page 63" href="http://viewer.zmags.com/publication/76f7d9a8?page=63"> DIAGNOSIS AND MANAGEMENT OF OCCULT HEPATITIS </a> <a title="EMJ Hepatology 3.1 2015 page 64" href="http://viewer.zmags.com/publication/76f7d9a8?page=64"> HBs) and usually only very low levels of HBV DNA </a> <a title="EMJ Hepatology 3.1 2015 page 65" href="http://viewer.zmags.com/publication/76f7d9a8?page=65"> serum markers. It can be found in almost every pa</a> <a title="EMJ Hepatology 3.1 2015 page 66" href="http://viewer.zmags.com/publication/76f7d9a8?page=66"> The use of anti-HBs antibodies in HBsAg assays is</a> <a title="EMJ Hepatology 3.1 2015 page 67" href="http://viewer.zmags.com/publication/76f7d9a8?page=67"> HBV DNA before, during, and some months aft</a> <a title="EMJ Hepatology 3.1 2015 page 68" href="http://viewer.zmags.com/publication/76f7d9a8?page=68"> Table 2: Management of occult hepatitis B </a> <a title="EMJ Hepatology 3.1 2015 page 69" href="http://viewer.zmags.com/publication/76f7d9a8?page=69"> 2001;7:51-8. 22. Abdelmalek MF et al. Subcli</a> <a title="EMJ Hepatology 3.1 2015 page 70" href="http://viewer.zmags.com/publication/76f7d9a8?page=70"> OCCULT HBV INFECTION REACTIVATION IN </a> <a title="EMJ Hepatology 3.1 2015 page 71" href="http://viewer.zmags.com/publication/76f7d9a8?page=71"> HBV DNA in the serum, in individuals with negativ</a> <a title="EMJ Hepatology 3.1 2015 page 72" href="http://viewer.zmags.com/publication/76f7d9a8?page=72"> HBV DNA positive and this test may provide false-</a> <a title="EMJ Hepatology 3.1 2015 page 73" href="http://viewer.zmags.com/publication/76f7d9a8?page=73"> combination of rituximab with cyclophosphamide, h</a> <a title="EMJ Hepatology 3.1 2015 page 74" href="http://viewer.zmags.com/publication/76f7d9a8?page=74"> NHL patients receiving systematic chemotherapy </a> <a title="EMJ Hepatology 3.1 2015 page 75" href="http://viewer.zmags.com/publication/76f7d9a8?page=75"> Similarly in 2009, Yeo et al.12 reported a study </a> <a title="EMJ Hepatology 3.1 2015 page 76" href="http://viewer.zmags.com/publication/76f7d9a8?page=76"> versus strict monitoring (which was the method us</a> <a title="EMJ Hepatology 3.1 2015 page 77" href="http://viewer.zmags.com/publication/76f7d9a8?page=77"> transplantation. Blood. 2009;113:3147-53. 17. Tur</a> <a title="EMJ Hepatology 3.1 2015 page 78" href="http://viewer.zmags.com/publication/76f7d9a8?page=78"> for non-Hodgkin lymphoma. Blood. 2002;99(2)</a> <a title="EMJ Hepatology 3.1 2015 page 79" href="http://viewer.zmags.com/publication/76f7d9a8?page=79"> HOMOZYGOSITY FOR THE C282Y SUBSTITUTION IN THE </a> <a title="EMJ Hepatology 3.1 2015 page 80" href="http://viewer.zmags.com/publication/76f7d9a8?page=80"> recently a mutation in GNPAT has been identified a</a> <a title="EMJ Hepatology 3.1 2015 page 81" href="http://viewer.zmags.com/publication/76f7d9a8?page=81"> Types 1-3 are autosomal recessive and affec</a> <a title="EMJ Hepatology 3.1 2015 page 82" href="http://viewer.zmags.com/publication/76f7d9a8?page=82"> Both subtypes are inherited in an autosomal</a> <a title="EMJ Hepatology 3.1 2015 page 83" href="http://viewer.zmags.com/publication/76f7d9a8?page=83"> years, and it is rare for SF to rise significantly</a> <a title="EMJ Hepatology 3.1 2015 page 84" href="http://viewer.zmags.com/publication/76f7d9a8?page=84"> However, in those with elevated SF, venesection i</a> <a title="EMJ Hepatology 3.1 2015 page 85" href="http://viewer.zmags.com/publication/76f7d9a8?page=85"> 845G--> A (C282Y) HFE hereditary haemochromat</a> <a title="EMJ Hepatology 3.1 2015 page 86" href="http://viewer.zmags.com/publication/76f7d9a8?page=86"> EUROPEAN MEDICAL JOURNAL provides influential arti</a> <a title="EMJ Hepatology 3.1 2015 page 87" href="http://viewer.zmags.com/publication/76f7d9a8?page=87"> HOW I DIAGNOSE AND TREAT ACUTE (FULMINANT</a> <a title="EMJ Hepatology 3.1 2015 page 88" href="http://viewer.zmags.com/publication/76f7d9a8?page=88"> Close monitoring of organ systems, particula</a> <a title="EMJ Hepatology 3.1 2015 page 89" href="http://viewer.zmags.com/publication/76f7d9a8?page=89"> How do I Decide if Patients with ALF need Emergen</a> <a title="EMJ Hepatology 3.1 2015 page 90" href="http://viewer.zmags.com/publication/76f7d9a8?page=90"> SUBSCRIBE TO RECEIVE THE LATEST CATIONS PUBLI</a>